GlobeNewswire

MPP Global’s eSuite Supports Major OTT TV Plan for ProSiebenSat.1 Digital

Del

WARRINGTON, United Kingdom, Sept. 17, 2018 (GLOBE NEWSWIRE) -- MPP Global, the technology company that delivers eSuite, the world’s smartest subscription & billing platform, has been chosen by ProSiebenSat.1, the German media powerhouse, to drive their OTT platform that also supports their new joint venture 7TV with Discovery Communications.

ProSiebenSat.1 operates free-to-air commercial TV channels, pay TV channels, radio stations and related print businesses. Every day, 45 million TV households in Germany, Austria and Switzerland watch ProSiebenSat.1’s 14 free and pay TV channels, and their online presence via web, mobile, smart TV, apps and social media generates more than five billion video views annually.

ProSiebenSat.1 Digital is providing the digital outlets for the ProSiebenSat1 Group on web and mobile and is also the tech provider of the recently created joint venture between ProSiebenSat.1 and Discovery Communications. The joint venture is set up to launch a new, premium entertainment streaming service in Germany. The pioneering OTT platform will offer a full package of live streams, an extensive media library with local content, Hollywood productions and high-quality sports content. It will also incorporate the Eurosport Player and maxdome video-on-demand (SVOD & TVOD) portals.

The service will deliver an unrivalled digital entertainment experience for consumers and features a wide range of free content and attractively priced subscription tiers, with access to exclusive sports and movies.

Dirk Daumann, CTO, ProSiebenSat.1 Digital, explains: “To be successful with the ProSiebenSat.1 Digital Products and new OTT Platform, we wanted to replace our in-house subscription VOD solution with a much more flexible service, to support subscription management and alternative monetisation of our assets. This was when we discovered MPP Global’s eSuite platform.”

Explaining how ProSiebenSat.1 concluded that MPP Global was the chosen technology partner for the joint venture, Daumann said: “Right from the get-go, we realised that eSuite presented the most flexible and complete solution for our requirements and MPP Global shared our ambitions for the future.

“We chose eSuite mainly for its feature-richness and complete APIs, especially when it comes to the flexibility in defining products and subscriptions. The platform also brings unique features which provide us with the ability to upsell our services through metering and paywalls.

“In the future we envisage a model where we let consumers 'try before sign-up'. So, consumers can watch the start of one of our premium shows for free and, after getting a sneak preview, they can decide if they want to subscribe so they can enjoy the rest of the show. This kind of functionality is essential to the future of the consumer-friendly platform we are developing.”

Discussing the long-term vision for the ProSiebenSat1 Digital Products, Daumann concludes: “We want to put the consumer first and provide a range of alternative monetisation models for our content.”

Chris Cheney, CTO and Co-Founder, MPP Global, said: “ProSiebenSat.1’s project scope is particularly exciting as the company has big plans.

“eSuite is perfectly positioned to take ProSiebenSat.1’s VOD ambitions to the next level, giving them access to the functionality needed to monetise their content for a growing and more diverse audience.”

Chris Welsh, VP, TV & Sport, Europe, commented: “MPP Global is proud to welcome ProSiebenSat.1 as a new client. We share the same passions to create a compelling product offering that will engage, disrupt and entertain the German OTT market.”

Notes for Editors
About MPP Global
http://www.mppglobal.com MPP Global delivers eSuite, the world’s smartest subscription & billing platform providing TV and OTT companies with the freedom to innovate their digital monetisation strategy.

eSuite provides next generation lifecycle management that enables the identification, acquisition and retention of customers and maximises lifetime value.

With offices throughout the Americas, Europe, Middle East and Asia Pacific, MPP Global has an impressive track record of maximising customer lifetime value. Clients include Sky, Philips, Bonnier, EFL, Now TV, TP Vision, SF Anytime, BHD and Universal.

For further information, please contact:
Paul Rose, VP, Marketing, Europe at MPP Global
+44 (0) 844 873 1418 or paul.rose@mppglobal.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Brookfield Asset Management Announces Results of Annual and Special Meeting of Shareholders17.6.2019 12:55:00 CESTPressemelding

BROOKFIELD, NEWS, June 17, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (TSX: BAM.A, NYSE: BAM, Euronext: BAMA) today announced that at the company’s annual and special meeting of shareholders held on June 14, 2019 in Toronto, over 85% of Class A Limited Voting Shares (“Class A Shares”) voted in favour of a new management share option plan. In addition, at the meeting all eight nominees proposed for election to the board of directors by holders of Class A Shares and all eight nominees proposed for election to the board of directors by the holder of Class B Limited Voting Shares (“Class B Shares”) were elected. Detailed results of the vote for the election of directors are set out below. Management received the following proxies from holders of Class A Shares in regard to the election of the eight directors nominated by this shareholder class: Director Nominee Votes For % Votes Withheld % M. Elyse Allan 731,503,129 99.60 2,926,448 0.40 Angela F. Braly 730,750,957 99.50 3,67

VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®17.6.2019 12:00:00 CESTPressemelding

Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 years Seroprotection rates four weeks post-3rd vaccination of Sci-B-Vac® vs. Engerix-B® were statistically significantly higher in key subgroup analyses of adults age ≥ 18 years No safety signals observed – safety and tolerability consistent with known profile of the vaccine With positive PROTECT data, pending successful completion of CONSTANT study, submissions of BLA/MAA for approval in U.S., Europe, and Canada expected to begin mid-year 2020 VBI to host conference call and webcast today, Monday, June 17, 2019 at 8:00 AM ET CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive top-line results from the randomized, double-blind, pivotal Phase 3 study, PROTECT, designed to

VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CESTPressemelding

CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle